1 Oct 2024
Pulmonary artery thrombosis in Behcet's syndrome: a case seriesPublisher siteEuropean Heart Journal, Ocular Diseases and Behçet’s Syndrome
Active, last published 2026
In ocular diseases and behçet’s syndrome
Naima
Moatassim
Scholar“Research focused on Ocular Diseases and Behçet’s Syndrome and adjacent fields.”
Mohammed V University
Morocco
Claim Your ProfileMorocco1
H-index
2
Citations
Naima has not officially claimed their profile. If you are Naima, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
aima Moatassim is a researcher working on Ocular Diseases and Behçet’s Syndrome. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Naima's work has been cited 2 times across 1 active year. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Ocular Diseases and Behçet’s Syndrome×7Vasculitis and related conditions×5Venous Thromboembolism Diagnosis and Management×2Cerebral Venous Sinus Thrombosis×2Vascular Anomalies and Treatments×2
04 · Where I am
Affiliations
Affiliation on published researchMohammed V University, MoroccoDrawn from the institution listed on this researcher’s published work.
05 · Selected work
Recent publications
2 works1 Oct 2024
Vascular thrombosis and relapse-associated factors in Behcet's syndrome: a comprehensive analysis of 136 patientsPublisher siteEuropean Heart Journal, Ocular Diseases and Behçet’s Syndrome
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Naima?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you